A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,029,000 shares of NUVB stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,029,000
Previous 761,000 35.22%
Holding current value
$2.9 Million
Previous $2.22 Million 6.48%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.3 - $3.83 $616,400 - $1.03 Million
268,000 Added 35.22%
1,029,000 $2.37 Million
Q2 2024

Aug 09, 2024

SELL
$2.58 - $3.69 $551,346 - $788,553
-213,700 Reduced 21.92%
761,000 $2.22 Million
Q1 2024

May 13, 2024

SELL
$1.46 - $3.97 $742,309 - $2.02 Million
-508,431 Reduced 34.28%
974,700 $3.55 Million
Q4 2023

Feb 13, 2024

BUY
$0.96 - $1.53 $1.05 Million - $1.67 Million
1,093,131 Added 280.29%
1,483,131 $2.24 Million
Q3 2023

Nov 14, 2023

BUY
$1.26 - $2.1 $98,406 - $164,010
78,100 Added 25.04%
390,000 $523,000
Q2 2023

Aug 11, 2023

BUY
$1.56 - $1.84 $60,528 - $71,392
38,800 Added 14.21%
311,900 $561,000
Q1 2023

May 12, 2023

BUY
$1.6 - $2.48 $206,240 - $319,672
128,900 Added 89.39%
273,100 $453,000
Q4 2022

Feb 13, 2023

SELL
$1.68 - $2.5 $195,409 - $290,787
-116,315 Reduced 44.65%
144,200 $277,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $50,522 - $703,828
174,215 Added 201.87%
260,515 $584,000
Q2 2022

Aug 12, 2022

SELL
$3.24 - $5.85 $19,116 - $34,515
-5,900 Reduced 6.4%
86,300 $280,000
Q1 2022

May 13, 2022

BUY
$4.6 - $8.83 $195,959 - $376,158
42,600 Added 85.89%
92,200 $485,000
Q4 2021

Feb 11, 2022

SELL
$7.75 - $10.05 $6,200 - $8,040
-800 Reduced 1.59%
49,600 $422,000
Q3 2021

Nov 12, 2021

SELL
$7.78 - $10.0 $3.24 Million - $4.16 Million
-416,400 Reduced 89.2%
50,400 $501,000
Q2 2021

Aug 13, 2021

BUY
$9.22 - $14.48 $4.3 Million - $6.76 Million
466,800 New
466,800 $4.35 Million

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $613M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.